Literature DB >> 5540479

Reversal by levodopa of cholinergic hypersensitivity in Parkinson's disease.

M I Weintraub, M H Van Woert.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5540479     DOI: 10.1056/NEJM197102252840804

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  How critical is the blood-brain barrier to the development of neurotherapeutics?

Authors:  Carmen Kut; Stuart A Grossman; Jaishri Blakeley
Journal:  JAMA Neurol       Date:  2015-04       Impact factor: 18.302

Review 2.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

4.  Interaction of atropine-like drugs with dopamine-containing neurones in rat brain.

Authors:  M B Bowers; R H Roth
Journal:  Br J Pharmacol       Date:  1972-02       Impact factor: 8.739

5.  Levodopa and orphenadrine hydrochloride in Parkinsonism.

Authors:  R K Whyte; K R Hunter; D R Laurence; G M Stern; P Armitage
Journal:  Eur J Clin Pharmacol       Date:  1971-12       Impact factor: 2.953

6.  Modification of the tremorigenic activity of physostigmine.

Authors:  L M Ambrani; M H Van Woert
Journal:  Br J Pharmacol       Date:  1972-10       Impact factor: 8.739

7.  Postanoxic myoclonus. Treatment of a case with 5-hydroxytryptophane and a decarboxylase inhibitor.

Authors:  E Beretta; F Regli; G de Crousaz; A J Steck
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

8.  Drugs for Parkinson's disease reduce tremor induced by physostigmine.

Authors:  P Gothóni; M Lehtinen; M Fincke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-07       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.